IRLA NASDAQ
IRulya Therapeutics Inc.
1W: -7.2%
1M: +10.3%
3M: +45.4%
YTD: +966.0%
1Y: +1717.0%
3Y: +3133.6%
5Y: -43.9%
$32.48
+1.09 (+3.49%)
After Hours: $32.50 (+0.02, +0.08%)
Weekly Expected Move ±19.9%
$21
$27
$34
$41
$48
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$31.9M
52W Range15.1-910
Volume53,159
Avg Volume64,217
Beta1.33
Dividend—
Analyst Ratings
Company Info
CEOBrigette Roberts
Employees38
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-09
Websitequincetx.com
101 College Street
New Haven, CA 06510
US
New Haven, CA 06510
US
About IRulya Therapeutics Inc.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PATTERSON LEONE D | 0 | — | 2026-10-08 | |
| Bonuccelli Catherine | 0 | — | 2026-10-08 | |
| Valentine James Elwo | 0 | — | 2026-10-08 | |
| Wise John Drayton | 0 | — | 2026-10-08 | |
| Militello John | 0 | — | 2026-10-08 |